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Background. The inbred genetic hypercalciuric stone-
forming (GHS) rats develop calcium phosphate (apatite) stones
when fed a normal 1.2% calcium diet. The addition of 1% hy-
droxyproline to this diet does not alter the type of stone formed,
while rats fed this diet with 3% hydroxyproline form mixed
apatite and calcium oxalate stones and those with 5% hydrox-
yproline added form only calcium oxalate stones. The present
study was designed to determine the localization of stone for-
mation and if this solid phase resulted in pathologic changes to
the kidneys.
Methods. GHS rats were fed 15 g of the standard diet or
the diet supplemented with 1%, 3%, or 5% hydroxyproline
for 18 weeks. A separate group of Sprague-Dawley rats (the
parental strain of the GHS rats), fed the standard diet for a
similar duration, served as an additional control. At 18 weeks, all
kidneys were perfusion-fixed for structural analysis, detection
of crystal deposits using the Yasue silver substitution method,
and osteopontin immunostaining.
Results. There were no crystal deposits found in the kidneys
of Sprague-Dawley rats. Crystal deposits were found in the kid-
neys of all GHS rats and this Yasue-stained material was de-
tected only in the urinary space. No crystal deposits were noted
within the cortical or medullary segments of the nephron and
there was no evidence for tubular damage in any group. The
only pathologic changes occurred in 3% and 5% hydroxypro-
line groups with the 5% group showing the most severe changes.
In these rats, which form only calcium oxalate stones, focal sites
along the urothelial lining of the papilla and fornix of the urinary
space demonstrated a proliferative response characterized by
increased density of urothelial cells that surrounded the crys-
tal deposits. At the fornix, some crystals were lodged within
the interstitium, deep to the proliferative urothelium. There
was increased osteopontin immunostaining in the proliferating
urothelium.
Conclusion. Thus in the GHS rat, the initial stone forma-
tion occurred solely in the urinary space. Tubular damage was
not observed with either apatite or calcium oxalate stones. The
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apatite stones do not appear to cause any pathological change
while those rats forming calcium oxalate stones have a prolif-
erative response of the urothelium, with increased osteopontin
immunostaining, around the crystal deposits in the fornix.
Hypercalciuria is the most common metabolic abnor-
mality in patients with nephrolithiasis [1–7]. Hypercalci-
uria raises urine supersaturation with respect to the solid
phases of calcium oxalate and calcium phosphate enhanc-
ing the probability of nucleation and growth of crystals
into clinically significant stones [3]. Reversal of the hyper-
calciuria with thiazide diuretics, resulting in lowering of
supersaturation, has been shown to reduce clinical stone
formation in two long-term studies [8, 9].
To establish an animal model of hypercalciuria, we
have successively inbred 56 generations of the most hy-
percalciuric progeny of hypercalciuric Sprague-Dawley
rats each of which now excretes eight to ten times as much
urinary calcium as similarly fed controls [10–23]. The hy-
percalciuria is due to increased intestinal calcium absorp-
tion [22] coupled to a defect in renal calcium reabsorption
[16, 20] and enhanced bone mineral resorption [17], sug-
gesting a systemic dysregulation of calcium homeostasis
[21]. After eating standard rat chow (1.2% calcium) for
18 weeks, virtually all of these hypercalciuric rats form
kidney stones while there was no evidence of stone for-
mation in Sprague-Dawley controls [18]. Because of their
hypercalciuria and stone formation we have termed the
rats genetic hypercalciuric stone-forming (GHS) rats [10–
13, 15, 18, 23]. We have shown that the stones formed by
the GHS rats fed standard rat chow contain only calcium
and phosphate, without oxalate, and by x-ray diffraction
the stones are exclusively poorly crystalline apatite [11,
13, 15, 18].
We reasoned that the dietary provision of an oxalate
precursor would produce an increase in urinary oxalate.
We wished to avoid the commonly used oxalate precur-
sor ethylene glycol [24–27] as it results in severe, life-
threatening metabolic acidosis in mammals [28–31] and
appears to be nephrotoxic [32–34]. Instead, we fed the
GHS rats additional hydroxyproline, a common amino
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acid which is metabolized to oxalate [35]. We found that
an increase in dietary hydroxyproline increased urinary
oxalate excretion, supersaturation with respect to the cal-
cium oxalate solid phase, the ratio of calcium oxalate to
calcium phosphate supersaturation and led to the forma-
tion of calcium oxalate kidney stones [23].
In other rat models of kidney stone disease, especially
those rats given ethylene glycol, the crystal deposition
was associated with extensive tubular toxicity [24–27].
Thus, in the current study, we wished to determine the
site of initial stone formation and questioned whether
the calcium phosphate or calcium oxalate crystal depo-
sition caused tubular injury. We found that the calcium
phosphate crystals were found exclusively in the urinary
space and caused only indentation of the urothelium;
there was no tubular injury or proliferation. The rats
given the larger amounts of hydroxyproline (3% and 5%)
had pathologic changes in their kidneys. In these rats,
which form calcium oxalate stones, focal sites along the
urothelial lining of the papilla and fornix of the urinary
space demonstrated a proliferative response that always
surrounded the crystal deposits. At the fornix, some crys-
tals appeared to be lodged within the interstitium, deep
to the proliferative urothelium and there was increased
osteopontin immunostaining in these areas.
METHODS
Establishment of hypercalciuric rats
Adult Sprague-Dawley rats (Charles River Laborato-
ries, Kingston, NY, USA) were screened for hypercal-
ciuria by placing the rats in individual metabolic cages,
feeding them a constant amount of a standard calcium
diet, and measuring urine calcium excretion. The most
hypercalciuric male and female rats were used to breed
the next generation. A similar protocol was used for
screening and inbreeding of subsequent generations as
described previously [10–23].
Study protocol
Twenty-nine 56th generation male GHS rats, initially
weighing on average 315 g, were placed in metabolic cages
for 18 weeks. Each rat was initially provided with 13 g/day
of food, an amount that we have previously shown is com-
pletely consumed by a rat of this size [36]. At 12 weeks,
the amount of food was increased to 15 g/day to account
for the increased dietary needs of the now larger rats
[23]. Any rat that ate less than 12 g of food per day until
week 12 or ate less than 14 g of food per day from week
12 until the conclusion of the study or drank less than
15 mL of water on any day would have been excluded
from the remainder of the study; however, all rats met
these prospective criteria throughout the study.
The male GHS rats were randomly divided into four
groups. As the GHS control, some GHS rats were fed
a standard 1.2% calcium, 0.65% phosphorus diet with-
out modification, while other rats were fed the same
diet supplemented with 1%, 3%, or 5% trans-4-hydroxy-
L-proline (hydroxyproline) (ICN Biomedicals, Aurora,
OH, USA). Male rats, as opposed to the female rats that
were used in a number of previous studies [10–13, 15, 16,
18], were used because of their greater baseline oxalate
excretion when fed this standard calcium diet [19]. As
an additional control, we fed Sprague-Dawley rats, the
strain from which the GHS rats were derived, the stan-
dard 1.2% calcium, 0.65% phosphorus diet without mod-
ification (Sprague-Dawley control). Previously we have
shown that GHS rats develop calcium phosphate (ap-
atite) stones when fed a normal 1.2% calcium diet [11,
13, 15, 18, 23]. The addition of 1% hydroxyproline to this
diet does not alter the type of stone formed, while rats fed
this diet with 3% hydroxyproline form mixed apatite and
calcium oxalate stones and those with 5% hydroxypro-
line added form only calcium oxalate stones [23]. Given
the consistency of stone type found in our prior study [23]
and the parallel design of the current study, we did not
analyze any stones formed by rats in the current study.
Rather, we assumed that the GHS rats fed the identical
diet, with or without an identical amount of hydroxypro-
line, for an identical period of time would form identical
types of stones as demonstrated previously [23]. Each of
the GHS groups consisted of seven rats (one rat initially
placed in the 5% hydroxyproline group was sacrificed
during the study due to an eye infection). The Sprague-
Dawley control group consisted of five rats.
At the end of 18 weeks, each rat received an intraperi-
toneal injection of sodium pentobarbital (Nembutal) to
induce complete anesthesia. The aorta was cannulated
and the kidneys were perfused with 0.9% saline irriga-
tion solution for ∼30 seconds resulting in the kidneys
lightening in color and the outflow from the vena cava
becoming clear. Then a buffered fixation solution of 2.5%
glutaraldehyde in 0.1 mol/L sodium cacodylate at pH
7.4 was perfused through the kidneys for ∼20 minutes
(∼100 mL) via a mechanical perfusion pump set at a flow
rate of 5 mL/min. Following perfusion, each kidney was
resected, placed in a labeled 15 mL Falcon tube filled with
the fixative buffer and refrigerated. Three kidneys, ap-
proximately equally divided between left and right, were
selected from each diet group for histologic analysis. The
kidneys were coded in Rochester and sent to Indianapo-
lis for histologic evaluation where they were analyzed
in a blinded manner. Only when the histologic analysis
was complete, and all photographs taken, was the code
broken.
Histologic analysis
Following 2 weeks of fixation, the upper and lower
poles of each kidney were removed and the kidney was
placed in an embedment cassette such that perfect cross
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sections of the entire kidney (including the renal papilla)
could routinely be obtained. All kidney specimens were
dehydrated through a series of graded ethanol concen-
trations to 100% ethanol before embedment in a 50/50
mixture of Paraplast Xtra (Fisher Scientific, Itasca, IL,
USA) and Pell-Away MicropCut (Polysciences, Inc., War-
rington, PA, USA). Serial 4 lm sections were cut on a
standard microtome and stained for histologic analysis
with hematoxylin and eosin (H&E), periodic acid-Schiff
hematoxylin (PASH) or picro sirius red and for calcium
deposits using the Yasue method [37]. The Yasue method
uses 5% aqueous silver nitrate and rubeanic acid to gen-
erate a dark brown to black histochemical staining of cal-
cium deposits. Sites of crystal location were identified in
the Yasue stained sections, then correlated with regions
of renal injury observed in the H&E, PASH or picro sirius
red–stained sections.
Another series of sections were cut at 4 lm on a stan-
dard microtome and placed on charged slides (Fisher
Scientific, Itasca, IL, USA) for osteopontin localization
by immunohistochemistry performed according to the
peroxidase-antiperoxidase (PAP) method of Sternburger
[38]. Subsequently, these slides were deparaffinized and
rehydrated through graded alcohols and blocked for non-
specific protein binding using 20% normal goat serum
in 0.1 mol/L phosphate-buffered saline (PBS) at room
temperature for 2 hours. The primary antibody, LF-123,
was a rabbit antihuman osteopontin antibody [39] ob-
tained as a gift from Dr. Larry Fisher at NIH and was
used at 1:150 dilution. The secondary antibody was a goat
antirabbit IgG (1:100) while the tertiary antibody was
a rabbit-PAP (1:600). Both the secondary and tertiary
antibodies were purchased from Jackson ImmunoRe-
search (West Grove, PA, USA). The diluant for all an-
tibodies was a 2% solution of normal goat serum in 0.1
mol/L PBS. Slides were incubated with the primary an-
tibody overnight at room temperature followed by sev-
eral rinses in PBS. Slides were subsequently incubated
with secondary and tertiary antibodies at room tempera-
ture for 1 hour each, with several PBS rinses between
each change of antibody. DAB (3,3-diaminobenzidine
tetahydrochloride) in Tris-HCl buffer was used as the
chromogen. All sections were covered with DAB so-
lution (0.05 mol/L Tris-HCl, 0.001% hydrogen perox-
ide, and 0.10% DAB), and incubated for approximately
10 minutes. Finally, each slide was rinsed well with
buffer, dehydrated and mounted with Permount (Fisher
Scientific) for viewing.
RESULTS
Spraque-Dawley control
This group of male animals is the parental strain of the
GHS rats. At time of sacrifice no stones or crystals were
found in the kidney or the urinary space (Fig. 1A to C). By
light microscopic examination no evidence of tubular in-
jury was found in any segments of the nephron, or the ad-
joining vasculature. The urothelium appeared of uniform
thickness. Osteopontin immunostaining was localized to
cells of the thick ascending limbs, distal tubules, cortical
collecting tubules, inner medullary collecting ducts, and
urothelium (Fig. 1A).
GHS control
This group of male animals was fed the standard diet
without any modifications. At the time of sacrifice stones
of varying sizes were only found in the urinary space
(Fig. 1D and E). Fed the standard calcium diet, the GHS
rats form only poorly crystalline apatite (calcium phos-
phate) stones [10–13, 18, 23]. No stones or crystals were
identified in cortical or medullary tubular lumens or the
interstitium. Occasional sites along the urothelial lining
of the renal papilla showed evidence of indentation from
adjacent crystals (Fig. 1E) but the urothelium appeared
uniform in thickness. Like the Sprague-Dawley controls,
using light microscopy, no tubular, vascular, or urothelial
injury was detected (Fig. 1E). The osteopontin immunos-
taining pattern was identical to that seen in the Sprague-
Dawley controls, which included cells of the thick
ascending limbs, distal tubules, cortical collecting
tubules, inner medullary collecting ducts, and urothelium
(Fig. 1D).
GHS animals fed hydroxyproline
The animals fed the 1% hydroxyproline supplemented
diet formed stones only in the urinary space, just as the
GHS control animals, and all stones were composed of ap-
atite (Fig. 2A) [23]. No stones or crystals were identified in
tubular lumens or the interstitium. An occasional site of
crystal indentation of the urothelium from nearby crys-
tals was present (Fig. 2B), another observation similar
to the GHS controls. In addition, using light microscopy,
no evidence of injury to cells of nephron, vasculature, or
urothelium was detected. Osteopontin immunostaining
was identical to that seen in the Sprague-Dawley con-
trols, which was localized to cells in the thick ascending
limbs, distal tubules, inner medullary collecting ducts, and
urothelium (Fig. 2A).
All animals fed the 3% hydroxyproline supplemented
diet formed stones only in the urinary space with no
evidence of stones or crystals in tubular lumens or the
interstitium (Fig. 2C). Stone composition changed to a
mixture of calcium oxalate dihydrate, calcium oxalate
monohydrate, and apatite [23]. Using light microscopy,
no changes were noted in cells of the nephron; however,
the urothelial lining of the renal papilla and renal pelvis
demonstrated focal sites of proliferation noted as an in-
creased thickness (Fig. 2D). Additional changes observed
in the urothelium included indentation from adjacent
crystals and entrapment of crystals primarily in the fornix
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Fig. 1. Midtransverse paraffin sections through a kidney from a
Sprague-Dawley control rat fed the standard diet (A, B, and C) and
a genetic hypercalciuric stone-forming (GHS) control rat on the stan-
dard diet (D and E). Each midtransverse kidney section is shown with
half of the kidney stained by the Yasue method and the other half with
an immunohistochemical stain for osteopontin. No tissue injury was
noted in either of the kidneys (B, C, and E). No stones were found in
the kidneys of the Sprague-Dawley controls while apatite stones were
only found in the renal pelvis of the GHS control. An identical pattern
of osteopontin immunostaining, localized to cells of the thick ascending
limbs, distal tubules, inner medullary collecting ducts and urothelium,
was observed in both control kidneys [magnification ×10 (A); ×40 (B);
×40 (C); ×10 (D); and ×20 (E)].
of the renal pelvis (Fig. 2D). Crystal entrapment was con-
firmed by observing a series of serial sections of these kid-
neys. Clearly, the proliferating urothelial cells surrounded
the crystalline deposits, isolating the crystals within or
beneath the urothelium. The osteopontin immunostain-
ing of the nephron segments was identical to that seen
in the Sprague-Dawley controls; however, those regions
of urothelial proliferation showed increased staining
(Fig. 2C).
Animals fed the 5% hydroxyproline supplemented diet
also formed stones only in the urinary space (Fig. 3). All
stones were calcium oxalate dihydrate and calcium ox-
alate monohydrate [23]. Using light microscopy, no crys-
tals or cellular injury was noted along any segments of
the nephron. However, these animals demonstrated more
extensive urothelial proliferation that occurred along the
entire length of the renal papilla to the fornix. Because of
the greater amount of urothelial proliferation, crystal en-
trapment was seen more frequently and gave the appear-
ance of crystals lodged within the interstitium, deep to the
proliferative urothelium. While the pattern of osteopon-
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Fig. 2. Midtransverse paraffin sections through a kidney from a GHS
rat fed the 1% hydroxyproline supplemented diet (A and B) and a
genetic hypercalciuric stone-forming (GHS) rat fed the 3% hydrox-
yproline supplemented diet (C and D). Animals in both groups had
stones only in the urinary space. No crystals or cell injury was identified
in any cortical or medullary tubules. Urothelial changes were noted in
both groups. The rats that ate the 1% hydroxyproline supplemented
diet showed indentation of the urothelium by adjacent stones while the
urothelium of the rats that ate the 3% hydroxyproline supplemented
diet showed urotheial proliferation, indentation and crystal entrapment
(D). Osteopontin immunostaining was unchanged in the 1% hydrox-
yproline group while the 3% hydroxyproline group showed increased
osteopontin staining of the urothelium at those sites of proliferation
[magnification ×10 (A); ×20 (B); ×10 (C); and ×20 (D)].
tin immunostaining of cortical and medullary nephron
segments was identical to the Sprague-Dawley controls,
sites of urothelial proliferation and crystal entrapment
showed intense staining (Figs. 3A and 4). Osteopontin
staining was also observed surrounding the stones.
DISCUSSION
Selecting for hypercalciuria, we have inbred Sprague-
Dawley rats to establish a strain of animals whose urine
calcium excretion is eight- to tenfold greater than that
of similarly fed noninbred Sprague-Dawley rats [10–23].
While consuming a standard calcium diet, these hypercal-
ciuric rats spontaneously form large numbers of poorly
crystalline apatite (calcium phosphate) kidney stones
[10–13, 18]. However, when the diet is supplemented with
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Fig. 3. Midtransverse paraffin sections
through a kidney from a genetic hypercal-
ciuric stone-forming (GHS) rat fed the 5%
hydroxyproline supplemented diet (A, B, C.
and D). These animals consistently possessed
stones only in the urinary space but not in
any nephron segments. No tubular injury
was detected. However, extensive urothelial
proliferation was noted along the side of
the renal papilla extending to the fornix.
Crystal entrapment was common at those
sites of proliferation leading to isolation of
some crystal from the urinary space. While
osteopontin immunostaining of cortical and
medullary nephron segments was identical
to that described for the Sprague-Dawley
controls, sites of urothelial proliferation and
crystal entrapment showed intense staining
[magnification ×10 (A); ×10 (B); ×25 (C);
and ×20 (D)].
5% hydroxyproline, a common amino acid that is me-
tabolized to oxalate, the inbred hypercalciuric rats form
calcium oxalate stones [23]. The addition of 3% dietary
hydroxyproline leads to the production of both apatite
and calcium oxalate stones while 1% added hydroxypro-
line does not change the character of the stones. The pur-
pose of the current study was to determine the localiza-
tion of the initial stone formation and ascertain if the
renal parenchyma exhibited a reaction to the stones. We
found that all stones were located in the urinary space and
the calcium oxalate, but not calcium phosphate, crystals
induced cellular proliferation resulting in stone seques-
tration and were associated with increased osteopontin
staining.
Osteopontin is an acidic, glycosylated, phosphopro-
tein that is secreted by renal tubular cells [40–42] and
has been detected in regions of stone formation in both
humans and rats [43, 44]. Osteopontin has been shown
to inhibit both calcium oxalate and calcium phosphate
crystallization in vitro and is also thought to inhibit crys-
tal formation in vivo [40, 41, 45–47]. In this study, in-
tense staining for osteopontin was associated with the
proliferative urothelial cells surrounding the calcium ox-
alate crystals. However, there did not appear to be in-
creased osteopontin staining in the urothelium of rats that
formed calcium phosphate stones. In these rats, the crys-
tals did not generate the proliferative response that was
observed with calcium oxalate crystals. Prior studies have
demonstrated an association of osteopontin with calcium
phosphate crystallization [45, 47]. Perhaps the lack of
entrapment of the calcium phosphate stones by the
urothelium, resulting in less crystal-cell interaction, ex-
plains the lack of up-regulation of osteopontin in this
study.
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Fig. 4. High magnification views of selected areas of the osteopontin
stained section seen in Figure 3. (A) Osteopontin staining of the cortical
distal and collecting tubules. The distal tubules stained more intensely
than the collecting tubules. (B) Osteopontin staining of the thick as-
cending limbs. (C) A site of proliferation of the urothelium at the fornix.
Intense osteopontin staining is observed in the proliferated urothelial
cells and nearby stone material. (D) A similar region of urothelial pro-
liferation and osteopontin staining at the side of the papillary tip of
nearby stone material [magnification ×25 (A); ×25 (B); ×25 (C); and
×20 (D)].
Our observation of calcium oxalate crystal entrapment
at sites of urothelial cell proliferation near or at the fornix,
which leads to the positioning of these crystals beneath
the urothelium, has been previously documented. In hu-
mans, Carr [48] described a process by which calcium
oxalate crystals would be moved from the urinary space
to lymphatic channels at the surface of renal papilla and
form forniceal “geodes.” In rats, Lilien et al [49] reported
a similar observation in animals fed a pyridoxine (vitamin
B6)-deficient diet. These authors also proposed a pathway
by which calcium oxalate crystals in the urinary space
would be entrapped by the urothelium and then moved
to the interstitium to be accessible to renal tubules or lym-
phatics. The morphologic data from our present GHS rat
study strongly suggests that the calcium oxalate, and not
calcium phosphate, crystals in the urinary space initiate
a proliferative response in the cells of the urothelium.
After this mitogenic process progresses, nearby calcium
oxalate crystals become entrapped and are moved to the
interstitial side of these cells as the urothelium continues
to thicken. Because we never see calcium oxalate crys-
tals in tubular lumens or deposition beneath the normal
urothelial cells, we have concluded that the calcium ox-
alate crystals found beneath the urothelium at the fornix
originated from the urinary space.
The calcium oxalate, but not the calcium phosphate,
solid phases induced proliferation of the urothelium.
Previous studies in several renal cell lines, including
porcine normal kidney tubular epithelial cells (LLC-
PK1), African green monkey cells (BSC-1), Madin-
Darby canine kidney cells (MDCK) and the primary
human renal proximal tubular epithelial cells (RPTEC)
have shown that oxalate induces immediate early re-
sponse genes, leading to increased DNA synthesis and
cellular proliferation [50–53]. The findings of the current
study, that calcium oxalate crystals induce cellular prolif-
eration, are in accord with these prior in vitro studies.
In vitro, calcium oxalate crystals have been shown to
bind in a stereo-specific manner to renal tubular cells [54].
Following binding, the cells react to the solid phase by in-
ternalizing the crystals, which promote changes in gene
expression and cytoskeletal organization and induce cel-
lular proliferation [55–58]. In the current study, while we
did not observe internalization of the crystals, we did ob-
serve marked proliferation of the urothelium in direct
contact with calcium oxalate crystals. This proliferation
indicates almost certain alteration in gene expression and
cytoskeletal organization. There was no apparent cellu-
lar proliferation in response to the calcium phosphate
crystals. Further studies will be necessary to determine
the mechanism(s) by which the interaction of the cal-
cium oxalate, but not calcium phosphate, crystals with
the urothelial cells induces proliferation.
Finlayson and Reid [59] reasoned that since the renal
ultrafiltrate traverses the tubule in a matter of minutes
there is insufficient time for ions to nucleate and then
aggregate into a clinically significant stone. Some have
postulated that the adherence of the crystals to the
urothelium would allow sufficient time for crystal aggre-
gation and stone formation. In the current study, crystals
were not found adherent to the tubular lumen but only
found in the urinary space. The crystals did not appear to
be adherent to cells, rather the calcium oxalate crystals lo-
cated in the fornix appeared to be trapped by the prolifer-
ating urothelium. Perhaps these calcium oxalate crystals
cannot be rapidly cleared due to the absence of directed
urinary flow in the fornix resulting in crystal trapping and
subsequent cellular proliferation.
Ethylene glycol added to the drinking water of rats
induces the rapid formation of calcium oxalate kidney
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stones. Histologic analysis of the kidneys from these rats
reveal marked cellular damage, including disruption of
the proximal and distal tubules with apoptosis and necro-
sis [26, 27, 51, 53]. These cellular degradation products
are thought to induce heterogeneous nucleation of cal-
cium oxalate crystals at physiologic tubular concentra-
tions of oxalate. Markers of cell injury are expressed. In
the current study, using only light microscopy, we did not
observe evidence of tubular cell disruption or injury. Per-
haps the difference between the cellular response of the
rats in this study and that observed after ethylene glycol
administration is due to the cellular toxicity observed af-
ter ethylene glycol administration [32–34]. Poldelski et al
[34] demonstrated that the metabolites of ethylene gly-
col induce multisystem organ injury. In isolated mouse
tubular segments and in renal tubular cell lines, they
found that principle metabolites of ethylene glycol, gly-
coaldehyde and glyoxylate, were both highly toxic, caus-
ing profound adenosine triphosphate (ATP) depletion,
lactate dehydrogenase (LDH) release, and Human Renal
Proximal Tubular cell (HK2) death. Neither oxalate nor
ethylene glycol itself induced this cellular toxicity. Addi-
tionally ethylene glycol administration results in severe,
life-threatening metabolic acidosis [28–31]. Thus, the re-
nal tubular cellular injury induced by ethylene glycol may
be a function of the metabolites of ethylene glycol and/or
the metabolic acidosis induced by metabolism of ethylene
glycol and not oxalate or calcium oxalate crystals.
Evan et al [60] have recently demonstrated that in hy-
percalciuric calcium oxalate stone formers the initial site
of crystal deposition is the interstitium surrounding the
thin limb of Henle’s loop. There is crystal extension to
the collecting tubule and then to the papilla, which then
erodes into the urinary space. The initial crystal phase is
apatite, a calcium phosphate complex, which can be a het-
erogenous nucleation site for calcium oxalate crystal for-
mation in the urinary space. In patients who form stones
after intestinal bypass procedures the crystals, again com-
posed of calcium phosphate, initially form in the collect-
ing duct where they act as a nucleating site for calcium
oxalate crystals. Thus, the initial site of crystal deposi-
tion appears dependent upon the principle mechanism
of stone formation [61]. Similar to humans, the GHS rats,
not given hydroxyproline, form a calcium phosphate solid
phase [10–13, 18, 23]. Why the initial site of stone forma-
tion in the GHS rats given hydroxyproline differs from
the initial site of stone formation in these human studies
is unclear. Perhaps the difference is due to the relative
rapidity of stone formation in the GHS rat compared to
humans. It is possible that with future study, other mech-
anisms of stone formation in humans, will more closely
resemble that in the GHS rat.
As in the GHS rat, the crystal phase initially deposited
in humans is composed of calcium and phosphate [60].
In the GHS rats, only with the addition of hydroxypro-
line to increase urine oxalate excretion, did the rats form
calcium oxalate stones [23]. The urine of the GHS rats,
without the addition of hydroxyproline, is markedly su-
persaturated not only with respect to calcium phosphate
but with respect to calcium oxalate as well. The initial
calcium phosphate crystal formation in the GHS rat ap-
pears due to an increase in the upper limit of metastabil-
ity with increasing urinary supersaturation with respect
to calcium oxalate but not to calcium phosphate [15]. The
increase in the upper limit of metastability with respect to
calcium oxalate would decrease the likelihood of form-
ing this solid phase. A similar increase in the upper limit
of metastability with respect to calcium oxalate, but not
calcium phosphate, to that observed in the GHS rat has
been confirmed in humans [62].
Thus we have demonstrated localization and tissue re-
action to the stones formed by the GHS rats. We have
shown that all stones appear to be localized to the uri-
nary space and that the calcium oxalate, but not the cal-
cium phosphate, stones induce marked proliferation of
the urothelium resulting in sequestration of the stones.
Osteopontin is induced and may help to retard further
stone formation. The mechanisms by which the calcium
oxalate, but not the calcium phosphate stones induce the
cellular proliferation and by which the sequestration oc-
curs only in the fornix, remain to be determined.
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